Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-05-22

Clinical Trial Update: Efficacy and Tolerability of Ginkgo Biloba Extract in Patients With Raynaud´s Phenomenon [Phase 2]

View source ↗

Summary

Phase 2 trial reports on the efficacy and tolerability of Ginkgo Biloba Extract for Raynaud's phenomenon; results have been posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Ginkgo biloba extract (Ginkgo biloba extract)

Snippet

Sponsor: VSM Geneesmiddelen b.v. | Conditions: Raynaud Disease | Phase 2 | Status: COMPLETED | Results posted: 2017-05-22